O
KERX

OppenheimerFunds’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

OppenheimerFunds’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-966,858
Closed -$12.3M – 983
2015
Q1 		$12.3M Buy
966,858
+16,666
+2% +$214K 0.01% 715
2014
Q4 		$13.4M Buy
950,192
+104,355
+12% +$1.62M 0.02% 694
2014
Q3 		$11.6M Sell
845,837
-1,568
-0.2% -$24K 0.01% 713
2014
Q2 		$13M Buy
847,405
+25,140
+3% +$356K 0.01% 706
2014
Q1 		$14M Buy
822,265
+53,427
+7% +$806K 0.02% 686
2013
Q4 		$9.96M Sell
768,838
-141,792
-16% -$1.69M 0.01% 739
2013
Q3 		$9.2M Sell
910,630
-1,084
-0.1% -$9.65K 0.01% 719
2013
Q2 		$6.81M Buy
+911,714
New +$7.12M 0.01% 745

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

OppenheimerFunds's KERX Position: Q2 2015 in Review

OppenheimerFunds sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 966,858 shares — an estimated $12.3M sold.

OppenheimerFunds first reported a position in KERX in Q2 2013 and held it in 8 quarters. The position peaked at $14M in Q1 2014. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • OppenheimerFunds reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • OppenheimerFunds sold 966,858 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $12.3M.
  • OppenheimerFunds first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 8 quarters.
  • OppenheimerFunds's Keryx Biopharmaceuticals Inc position peaked at $14M in Q1 2014.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on OppenheimerFunds's 13F filing for Q2 2015, filed 6 Aug 2015.